Federal courts have rejected a drug firm’s request to order the Food and Drug Administration to restore the homeopathic drug oversight policy it withdrew in 2019 but are allowing the firm to continue litigating its complaint seeking the change.
While the decisions by the US Circuit Court and the US District Court for the District of Columba are on a complaint that MediNatura Inc. filed in response to FDA enforcement against its Rx drugs, the firm also markets OTC homeopathics
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?